Solifenacin succinate (Vesicare) for the treatment of urinary incontinence in Parkinson's disease.

Trial Profile

Solifenacin succinate (Vesicare) for the treatment of urinary incontinence in Parkinson's disease.

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 30 Nov 2012

At a glance

  • Drugs Solifenacin (Primary)
  • Indications Urinary incontinence
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Oct 2010 Planned end date changed from 1 Nov 2008 to 1 Apr 2011 as reported by ClinicalTrials.gov.
    • 03 Jun 2008 Status changed from recruiting to withdrawn prior to recruitment as the investigators intend pursuing a larger, multi-site study, according to ClinicalTrials.gov
    • 22 Jan 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top